Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Platelet-Boosting drug speed recovery in kids with neuroblastoma?

NCT ID NCT06818916

Disease control Sponsor: Beijing Children's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests whether hetrombopag, a drug that stimulates platelet production, can help children with neuroblastoma recover their platelets faster after a stem cell transplant. Thirty children will take the drug daily for up to 6 weeks. The main goal is to see if it increases the rate of platelet engraftment, which could reduce the need for platelet transfusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hetrombopag (a drug that stimulates platelet production)
What this could lead to
If it works, this could offer a way to speed up platelet recovery after stem cell transplant, reducing the need for transfusions in children with neuroblastoma.
What could go wrong
This is a small, early-phase trial with only 30 children, so results may not apply broadly. The drug may not improve platelet engraftment or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age\<18 years old; * Diagnosed as neuroblastoma; * ECOG ≤ 2; * First time receiving autologous hematopoietic stem cell transplantation; * The subjects or their legal guardians agree to participate and sign the informed consent form. Exclusion Criteria: * ALT/AST \> 3 ULN, or TBIL \> 1.5 ULN; * Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment; * Suffering from thromboembolic diseases; * Other situations that are not suitable for inclusion in the study determined by researchers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autologous hematopoietic stem cell transplantation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autologous hematopoietic stem cell transplantation Delayed platelet engraftment Neuroblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.